Search research articles
Contact Us
Filters
Showing results (161-170 of 183) with videos related to
Page
of 19
Sort By:
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Clinical Breast Cancer
|
November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan, Beverly Moy, Janine Mansi, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
The Lancet. Oncology
|
November 4, 2021
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
Carlos H Barrios, Gustavo Werutsky, Alejandro Mohar, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 18, 2023
High resolution imaging and five-year tuberculosis contact outcomes
Hanif Esmail, Anna K Coussens, Friedrich Thienemann, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 183) with videos related to
Sort By:
Page
of 19
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Clinical Breast Cancer
|
November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan, Beverly Moy, Janine Mansi, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
The Lancet. Oncology
|
November 4, 2021
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
Carlos H Barrios, Gustavo Werutsky, Alejandro Mohar, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 18, 2023
High resolution imaging and five-year tuberculosis contact outcomes
Hanif Esmail, Anna K Coussens, Friedrich Thienemann, et al.
Page
of 19